Researchers looked at the characteristics of breast cancer found in patients under 40 years old.
A phase III trial tested trastuzumab emtansine (T-DM1) with or without pertuzumab in patients with HER2-positive metastatic breast cancer.
A phase III trial found bevacizumab and pemetrexed were effective as a maintenance therapy, but researchers do not recommend it to treat non–small-cell lung cancer.
Researchers tried using deep machine learning to anticipate disease outcomes and progression in patients with lung cancer.
The study tested whether patients with early breast cancer could benefit from adding olaparib to paclitaxel.
Researchers compared invasive disease-free survival rates in patients with breast cancer who took nanoparticle albumin-bound (NAB)-paclitaxel compared with those who took solvent-based (sb)-paclitaxel.
Researchers examined the results of ribociclib and letrozole as a treatment for patients with estrogen receptor-positive ovarian cancer and endometrial cancer.
A new study looked at the link between levels of lactobacilli species found in the cervicovaginal microbiome and the presence or risk of ovarian cancer.
A trial presented at ASCO 2019 found HER2 heterogenity can impact response rates to some treatments in HER2-positive breast cancer patients.
Patients responded relatively well to the phase I trial testing a new treatment for several malignancies, including gastric and gastroesophageal junction adenocarcinomas.